Literature DB >> 3671489

Early physiological effects of lithium treatment: electrooculographic and adaptometric findings in patients with affective and schizoaffective psychoses.

W P Kaschka1, T Mokrusch, M Korth.   

Abstract

Electrooculography allows to measure the fundocorneal potential, a standing potential of the eye, under the conditions of light and dark adaptation. The results are expressed as the so-called Arden ratio. As was demon-strated by others in healthy volunteers, the Arden ratio, on the average, de-creases under Lithium treatment. However, in individual cases it can also remain unchanged or even rise. We have performed electrooculographic and adaptometric examinations in ten patients with affective disorders (DSM-III, 296. XX) and schizoaffective psychoses (DSM-III, 295.70). The criteria for the assignment of patients to lithium treatment were derived from a study by Angst. Arden ratios were determined six times, respectively, before lithium application and after a therapeutic lithium serum level (0.6-0.8 mmol/l) had been reached (cf. 5). The values observed during lithium treatment were significantly lower than those measured before lithium application. Dark adaptation, as measured using an adaptometer according to Goldmann-Weekers, was disturbed under lithium. The potential predictor function of these findings with regard to the lithium response is being investigated by means of a prospective study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3671489     DOI: 10.1055/s-2007-1017104

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  2 in total

1.  Dark condition normalization of smooth pursuit tracking: evidence of cerebellar dysfunction in psychosis.

Authors:  R T Pivik; F W Bylsma; P M Cooper
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

Review 2.  Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.

Authors:  Ronald S Duman; Ryota Shinohara; Manoela V Fogaça; Brendan Hare
Journal:  Mol Psychiatry       Date:  2019-03-20       Impact factor: 15.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.